NcRNA-Mediated High Expression of HMMR as a Prognostic Biomarker Correlated With Cell Proliferation and Cell Migration in Lung Adenocarcinoma.

Background: Hyaluronan-mediated motility receptor (HMMR) plays a pivotal role in cell proliferation in various cancers, including lung cancer. However, its function and biological mechanism in lung adenocarcinoma (LUAD) remain unclear. Methods: Data on HMMR expression from several public databases were extensively analyzed, including the prognosis of HMMR in the Gene Expression Profiling Interactive Analysis (GEPIA) database. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were analyzed using DAVID and gene set enrichment analysis (GSEA) software. The correlation between HMMR expression and immune cell infiltration was analyzed in the Tumor Immune Estimation Resource (TIMER) database, and the gene and protein networks were examined using the GeneMANIA and STRING databases. Experimentally, the expression of HMMR in LUAD and lung cancer cell lines was determined using immunohistochemistry and quantitative RT-PCR assays. Besides, the function of HMMR on cancer cell proliferation and migration was examined using cell growth curve and colony formation, Transwell, and wound healing assays. Results: In this study, we found that HMMR was elevated in LUAD and that its high expression was associated with poor clinicopathological features and adverse outcomes in LUAD patients. Furthermore, our results demonstrated that the expression of HMMR was positively correlated with immune cell infiltration and immune modulation. Interestingly, diverse immune cell infiltration affects the prognosis of LUAD. In the functional assay, depletion of HMMR significantly repressed the cancer cell growth and migration of LUAD. Mechanically, we found that that the DNA methylation/TMPO-AS1/let-7b-5p axis mediated the high expression of HMMR in LUAD. Depletion of TMPO-AS1 and overexpression of let-7b-5p could result in the decreased expression of HMMR in LUAD cells. Furthermore, we found that TMPO-AS1 was positively correlated with HMMR, yet negatively correlated with let-7b-5p expression in LUAD. Conclusions: Our findings elucidated that the DNA methylation/TMPO-AS1/let-7b-5p axis mediated the high expression of HMMR, which may be considered as a biomarker to predict prognosis in LUAD.

MiR-4429 Alleviates Malignant Behaviors of Lung Adenocarcioma Through Wnt/ß-Catenin Pathway.

Lung adenocarcinoma (ADC) is a common subtype of non-small cell lung cancer. MicroRNAs have been reported to be effective biomarkers for diagnosis and an important target for therapy. MiR-4429 is a newly identified miRNA, which can take part in tumor progression as a tumor inhibitor. Moreover, it is an exosomal miRNA that can be taken by lung ADC cell line A549. Nevertheless, its role in lung ADC has been poorly studied. This research discovered that miR-4429 was low expressed in lung ADC cells. MiR-4429 mimics could alleviate the capacities of cell proliferation and metastasis. The mimics are able to reverse epithelial-mesenchymal transition at the same time. Furthermore, it was verified that miR-4429 could bind to ß-catenin and negatively regulate ß-catenin expression. Interestingly, SKL2001 can reverse the role of miR-4429 on tumor. Consequently, miR-4429 can inactivate Wnt/ß-catenin signaling pathway by targeting ß-catenin and prevent oncogene expression in lung ADC cells.

[Levels of activation markers of platelets in peripheral blood and their significance in patients with lung cancer].

BACKGROUND: Platelet activation often occurs in intermediate and advanced tumors, with increases of expression and release of platelet adhesion molecule. The aim of this study is to investigate the expression of activation markers of platelet and their significance in lung cancer. METHODS: The activation markers of platelet, CD62P and CD63, were detected in peripheral blood of 120 patients with lung cancer and 60 healthy persons by FCM method. RESULTS: The levels of peripheral blood CD62P and CD63 of lung cancer patients were significantly higher than those of healthy people (P < 0.01). In lung cancer group, the levels of peripheral blood CD62P and CD63 on the seventh postoperative day were significantly lower than those before operation and on the first postoperative day (P < 0.01). The levels of peripheral blood CD62P and CD63 before operation were closely related to size of tumor, lymph node status and TNM stages (P < 0.01), but not to cell differentiation, histology, age and sex of lung cancer patients (P > 0.05). CONCLUSIONS: Activation markers of platelet obviously increase in peripheral blood of lung cancer patients and they may play important roles in tumor growth and lymphatic metastasis. The levels of activation markers of platelet may be useful predictors for prognosis.